Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), today announced the close of its Series B funding round of $147.5 million. GV, LYFE Capital and Revelation Partners co-led the investment round with participation from additional new investors Newton Investment Management, Singapore-based global investor EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment and others.
IntelyCare Secures $115 Million Series C Financing Led by Janus Henderson Investors
IntelyCare, the leading tech-enabled nurse staffing platform for healthcare organizations in the United States, today announced it has secured $115 million in a Series C financing round led by Janus Henderson Investors, a leading global investment firm and asset manager. The funding, valuing IntelyCare at $1.1 billion, also includes investments by prominent new and existing investors, including Longitude Capital, Leeds Illuminate, Endeavour Vision, Revelation Partners, and Kaiser Permanente Ventures.
Gravie Secures $75 Million in Financing Led by Georgian
Gravie, a leading health benefits company, announced today that it has raised $75 million in a Series E round of financing led by Georgian, a growth-stage investor based in Canada, with participation from existing investors FirstMark Capital, AXA Venture Partners, Split Rock Partners and Revelation Partners. The capital will be used to fuel Gravie's continued growth through investments in all areas of the company including product and technology, sales and marketing, and expansion into new markets through new and existing distribution channels.
Omada Health Closes $192 Million Series E Financing to Bring Virtual-First Care to Millions
Omada Health, a chronic care integrated healthcare provider, announced its $192 million Series E funding round led by Fidelity Management & Research Company with participation from aMoon, existing investors Perceptive Advisors, Wellington Management, Civilization Ventures, and others.
Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic
Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors. Also participating in the round were new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi and existing investors Wellington Management, RA Capital Management and Moore Strategic Ventures.
Endeavor BioMedicines Closes $101M Series B Financing To Advance Clinical-Stage Precision Medicine Pipeline
Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
Akili Interactive (“Akili” or the “Company”), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp. I (“SCS”) (Nasdaq: DNAA), a special purpose acquisition company.
Immunocore Announces FDA Approval of KIMMTRAK® (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma
Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases today announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).
Digital Health Leader Verana Health Secures $150M Series E Funding Round
Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, today announced a $150 million Series E funding round led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings.
Vista Equity Invests $300 Million in Telehealth Software Firm TigerConnect Sources
Healthcare communications software provider TigerConnect has raised $300 million in growth investment from private equity firm Vista Equity Partners, sources familiar with the matter told Reuters on Monday. The valuation of TigerConnect wasn't known. It last raised $45 million at a valuation of $370 million in September 2020, according to PitchBook data, counting HealthQuest Capital and New Leaf Ventures as its backers.